Clinical trial · Observational
A Phase II Study of Parotid-gland Sparing IMRT in Patients With Midline Tumour of the Head and Neck
A Phase II Study of Parotid-gland Sparing Intensity-modulated Radiotherapy in Patients With Midline Tumour of the Head and Neck
NCT02149602CI-TRIAL-00014728PARSPORT-IIcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a phase II trial designed to test the feasibility of delivering IMRT to head and neck cancer patients with tumours arising in the midline (oropharynx and hypopharynx), and to assess possible improvement in reducing the incidence of xerostomia with bilateral superficial lobe parotid sparing IMRT.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hypopharyngeal Squamous Cell Cancer | — | UNRESOLVED | — |
| Oropharyngeal Squamous Cell Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intensity modulated radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- oropharyngeal and hypopharyngeal HNSCC
- description
- Intensity Modulated Radiotherapy HPV positive and HPV negative
- interventionNames
- Radiation: Intensity modulated radiotherapy
Primary outcomes (1)
- measure
- The proportion of patients reporting grade 2 or more xerostomia using subjective measure on the LENTSOMA late toxicity scoring scale one year after treatment.
- timeFrame
- 12 months
Secondary outcomes (3)
- measure
- Acute radiation toxicity
- timeFrame
- 0-3 months
- measure
- Late radiation toxicity
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * histologically confirmed locally advanced HNSCC arising from the oropharynx or hypopharynx with high risk of bilateral parapharyngeal space involvement Exclusion Criteria: * Patients \<18 years old or with a previous malignancy other than non-melanomatous skin cancer
References
Publications (0)
Data not yet available
No reference posted for this study.